Trial Profile
A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs MAXY G34 (Primary)
- Indications Breast cancer; Neutropenia
- Focus Therapeutic Use
- Sponsors Maxygen
- 26 May 2014 New trial record